GBR 12909 Study in Cocaine Experienced African American Volunteers - 1
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA)
First received: August 10, 2004
Last updated: October 23, 2007
Last verified: January 2005
The purpose of this study is to assess GBR 12909 in cocaine experienced African American Volunteers.
Drug: GBR 12909
||Primary Purpose: Treatment
||GBR 12909 Study in Cocaine Experienced African American Volunteers
Primary Outcome Measures:
- pharmacokinetic assessment
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Particular interest is being given to the hematological safety data.
|Ages Eligible for Study:
||18 Years to 45 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Must be within 20% of ideal body weight and must weigh at least 45 kg.
- Must understand the study procedures and provide written informed consent.
- Must meet DSM-4 criteria for abuse or dependence on cocaine.
- Must be non-treatment seeking at the time of the study.
- Please contact the study site for more information.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00089687
|Uniformed Services University of Health Science
|Bethesda, Maryland, United States, 20814 4799 |
||Louis Cantilena, M.D.
||Uniformed Services University of Health Science
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 10, 2004
||October 23, 2007
||United States: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 22, 2013
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs